Loading...
01/11 05:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects significant challenges: a steep decline in gross margins, increased net losses, and staffing issues. The Q&A highlighted uncertainties about engineering revenue and production delays, although management expressed optimism about resolving these issues. Despite a $5 million raise to improve financial health, there's no immediate shareholder return plan. The military program's continuity is positive, but overall, the financial performance and lack of clear guidance on key issues suggest a negative sentiment. The market is likely to react negatively, with a potential stock price decrease between -2% and -8%.
Revenue $4.2 million, down from $5.2 million year-over-year. The decrease was primarily due to production challenges, including low yields and a one-month shutdown of the single-use cystoscope line.
Production Revenue $3.2 million, up from $3 million year-over-year. This increase reflects growth in production despite the challenges faced.
Engineering Revenue $924,000, down from $2.3 million year-over-year. The decline was attributed to low yields and increased non-billable engineering activities.
Gross Margin 10%, down from 35% year-over-year. The drop was due to low yields, a one-month shutdown, and under absorption of engineering resources.
Net Loss $2.1 million, compared to a net loss of $317,000 in the same quarter last year. The increase in net loss was driven by lower revenue and gross profit.
Adjusted EBITDA Negative $1.3 million, compared to positive $52,000 in the same quarter last year. The decline was due to lower revenue and associated gross profit.
Cash Position Excess of $2.5 million at the end of March. During the quarter, approximately $5 million was raised, which helped pay down the revolving line of credit.
R&D Spending $211,000, up from $193,000 year-over-year. The increase was primarily due to investments in the Unity platform.
SG&A Expenses $2.2 million, up from $1.9 million year-over-year. The increase was mainly due to higher personnel costs, including stock-based compensation and recruiting expenses.
Unity Platform Launch: The Unity platform was launched in late January, designed to utilize standard baseline designs with modular subsystems for quick updates and customization.
Single-Use Cystoscope Production: Production of the single-use cystoscope faced challenges with yields dropping below 50%, but has since improved, with throughput currently double pre-shutdown levels.
New Product Development: Started production of a micro endoscope for ophthalmic procedures and a complex subassembly for retinal imaging, each generating $100,000 to $200,000 per quarter.
Aerospace Program Growth: Production revenue from the aerospace program increased from approximately $300,000 in Q1 to just under $900,000 in Q3, with expectations to double output in Q4.
Single-Use Endoscope Market Growth: The single-use endoscope market is growing at annual rates estimated to be as high as 20%, driven by lower costs and superior performance.
Production Challenges: Production challenges led to lower revenue and margins, with a shortfall of approximately $600,000 in Q3 due to low yields and delays.
Engineering Resource Allocation: Engineering resources were diverted to resolve production issues, impacting product development timelines.
Board Changes: Two new board members, Buell Duncan and JJ Pellegrino, bring extensive experience in medical device scaling and corporate management.
Customer Agreements: Finalized a purchase agreement with a customer for minimum annual commitments of nearly $4 million for 2025 and 2026.
Production Challenges: Significant lower revenue and margins due to production issues, including low yield, delivery delays, and reduced efficiency. A specific example is the single-use cystoscope, which experienced yields dropping to less than 50%, leading to a production halt and a shortfall of approximately $600,000 in Q3.
Staffing Issues: Challenges in recruiting, retaining, and training assembly technicians, particularly for a second shift, which contributed to production delays and inefficiencies.
Engineering Resource Allocation: Distraction of engineering resources from product development to resolve production issues, resulting in increased non-billable activities and lower overall productivity.
Customer-Related Delays: About $300,000 of product development revenue was delayed due to customer-imposed delays in one program and a delayed milestone in another project.
Gross Margin Decline: Gross margins fell to 10% from 35% year-over-year due to low yields and under absorption of engineering resources, impacting profitability.
Economic Factors: The overall economic environment and competitive pressures in the medical device market, particularly in the single-use endoscope segment, which is growing but also highly competitive.
Production Backlog: The company has the largest production backlog in over 20 years, indicating strong demand for its products.
Unity Platform: The Unity platform, launched in late January, is designed to revolutionize endoscopic system development, reducing risk, cost, and time to market.
Single-Use Cystoscope: The single-use cystoscope program is a major driver of production growth, with plans to expand output by adding a second production line.
Aerospace Program: Production levels from the aerospace program are expected to set new records in Q4, with a commitment of nearly $4 million in annual purchase agreements.
Board Changes: New board members with relevant experience have been appointed to strengthen the company's strategic direction.
Q4 Revenue Expectations: The company expects to achieve $6 million in sales in Q4, driven by strong demand and production ramp-up.
Gross Margin Recovery: Gross margins are expected to recover as manufacturing scales and revenues increase, particularly in Q4.
Adjusted EBITDA Outlook: The company anticipates reaching positive adjusted EBITDA in Q4 as production volume increases.
Production Capacity: The company aims to double output quarter over quarter in its aerospace program and other production lines.
Shareholder Return Plan: The company raised approximately $5 million during the quarter, which was used to pay down their revolving line of credit and deploy working capital. However, there was no specific mention of a share buyback program or dividend program in the call.
The earnings call indicates strong revenue growth, especially in key manufacturing programs, and an optimistic outlook for fiscal 2026 with improved gross margins and positive adjusted EBITDA. The Q&A section did not reveal significant negative trends, and the company's strategic expansion into defense aerospace alongside medical devices suggests diversification and potential profitability. Despite some concerns over gross margins and delayed orders, the overall sentiment is positive, supported by strong revenue expectations and strategic operational investments.
The earnings call reveals record-high quarterly revenue and a significant increase in production revenue, despite a decline in gross margin. The Q&A section confirms conservative but optimistic guidance, with expectations of improved gross margins and a well-prepared pipeline. Management's clear responses and strategic focus on production and engineering projects suggest a positive outlook. The stock price is likely to react positively, with potential gains of 2% to 8% over the next two weeks.
The earnings call reflects significant challenges: a steep decline in gross margins, increased net losses, and staffing issues. The Q&A highlighted uncertainties about engineering revenue and production delays, although management expressed optimism about resolving these issues. Despite a $5 million raise to improve financial health, there's no immediate shareholder return plan. The military program's continuity is positive, but overall, the financial performance and lack of clear guidance on key issues suggest a negative sentiment. The market is likely to react negatively, with a potential stock price decrease between -2% and -8%.
The earnings call reveals a challenging financial situation with declining revenue, gross margin, and increased net loss. Despite a positive backlog and future purchase commitments, the weak financial performance and negative adjusted EBITDA are concerning. The Q&A highlights unresolved issues like tariffs and production delays, although management remains optimistic about future growth. However, the lack of clear guidance on key developments and ongoing expenses further clouds the outlook, suggesting a negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
